First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

被引：0
|
作者：
E. Van Cutsem
I. Danielewicz
M. P. Saunders
P. Pfeiffer
G. Argilés
C. Borg
R. Glynne-Jones
C. J. A. Punt
A. J. Van de Wouw
M. Fedyanin
D. Stroyakovskiy
H. Kroening
P. Garcia-Alfonso
H. Wasan
A. Falcone
R. Fougeray
A. Egorov
N. Amellal
V. Moiseyenko
机构：
[1] University Hospitals Leuven and KU Leuven,Julius Centre, University Medical Centre Utrecht
[2] Wojewodzkie Hospitals in Gdyni/Gdansk Medical University,Department of Oncology
[3] Christie Hospital NHS Foundation Trust,undefined
[4] Odense University Hospital,undefined
[5] Vall d’Hebrón Institute of Oncology and Vall d’Hebrón University Hospital,undefined
[6] University Hospital Besançon,undefined
[7] Mount Vernon Hospital,undefined
[8] Amsterdam University Medical Centres,undefined
[9] Utrecht University,undefined
[10] VieCuri Medical Centre,undefined
[11] Noord-Limburg,undefined
[12] NN Blokhin National Medical Research Centre of Oncology,undefined
[13] Moscow City Oncology Hospital N62,undefined
[14] Group Practice for Haematology and Oncology,undefined
[15] Gregorio Marañón General University Hospital,undefined
[16] Hammersmith Hospital,undefined
[17] Imperial College London,undefined
[18] University Hospital of Pisa,undefined
[19] Servier International Research Institute,undefined
[20] Saint Petersburg Scientific Practical Centre for Specialized Medical Care,undefined
来源：
British Journal of Cancer | 2022年 / 126卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1548 / 1554
页数：6
相关论文
共 50 条
  • [31] A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer
    Zou, Jiayun
    Wang, Yuanyuan
    Xu, Jiayu
    Li, Jinna
    Wang, Tianzhuo
    Zhang, Ying
    Bai, Yibo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [32] Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
    Xu, Wei
    Kuang, Meng
    Gong, Yang
    Cao, Chunxiang
    Chen, Jinfei
    Tang, Cuiju
    ONCOTARGETS AND THERAPY, 2016, 9 : 4833 - 4842
  • [33] Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer
    Shankaran, Veena
    Mummy, David
    Koepl, Lisel
    Bansal, Aaasthaa
    Mirick, Dana K.
    Yu, Elaine
    Morlock, Rob
    Ogale, Sarika
    Ramsey, Scott D.
    ONCOLOGIST, 2014, 19 (08): : 892 - 899
  • [34] Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
    Andre, Thierry
    Falcone, Alfredo
    Shparyk, Yaroslav
    Moiseenko, Fedor
    Polo-Marques, Eduardo
    Csoszi, Tibor
    Campos-Bragagnoli, Arinilda
    Liposits, Gabor
    Chmielowska, Ewa
    Aubel, Paul
    Martin, Lourdes
    Fougeray, Ronan
    Amellal, Nadia
    Saunders, Mark P.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (02): : 133 - 144
  • [35] Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis
    de Moraes, Francisco Cezar Aquino
    Pessoa, Felipe Dirceu Dantas Leite
    Ribeiro, Caio Henrique Duarte de Castro
    Fernandes, Marianne Rodrigues
    Burbano, Rommel Mario Rodriguez
    dos Santos, Ney Pereira Carneiro
    BMC CANCER, 2024, 24 (01)
  • [36] First-line cetuximab gives longer survival than bevacizumab in metastatic colorectal cancer
    Mayor, Susan
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2013, 74 (07) : 370 - 370
  • [37] Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
    Yoshino, Takayuki
    Taieb, Julien
    Kuboki, Yasutoshi
    Pfeiffer, Per
    Kumar, Amit
    Hochster, Howard S. S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [38] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    British Journal of Cancer, 2010, 102 : 1468 - 1473
  • [39] Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study
    Cirac, Paolo
    Conca, Veronica
    Moretto, Roberto
    Antoniotti, Carlotta
    Ambrosini, Margherita
    Murgioni, Sabina
    Gori, Giovanni
    Russo, Alessandra
    Bergamo, Francesca
    Randon, Giovanni
    Studiale, Vittorio
    Fini, Elisabetta
    Marmorino, Federica
    Borelli, Beatrice
    Germani, Marco Maria
    Vetere, Guglielmo
    Carullo, Martina
    Boccaccio, Chiara
    Masi, Gianluca
    Cremolini, Chiara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Bevacizumab in combination with chemotherapy: First-line treatment of patients with metastatic colorectal cancer
    Hochster, Howard S.
    SEMINARS IN ONCOLOGY, 2006, 33 (05) : S8 - S14
12345